Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
High-Yield Pearls for Management of Psoriasis with Therapeutic Updates
Description
The presentation outlines recent advancements in psoriasis treatment, focusing on new agents and their clinical implications. Bimikizumab (BIM Zelix) is highlighted as a leading therapy, functioning as a dual inhibitor of IL-17A and IL-17F, showcasing rapid efficacy with a significant percentage of patients achieving a PASI 100 score. It is particularly noted for its potential use in patients who have not responded to other biologics. Ducravacitinib (SOTYKTU), an oral tyrosine kinase 2 inhibitor, shows superior efficacy compared to traditional therapies like apremilast, with promising safety data regarding malignancy risk and laboratory abnormalities. New topical agents include Tapineroff, an aryl hydrocarbon receptor modulator demonstrating effectiveness for inverse psoriasis but with some concerns about side effects, and Reflumalast, a more potent PDE4 inhibitor suited for children. Updates on biosimilars include the FDA approval of Weslana, an interchangeable biosimilar to ustekinumab, and reassuring data about biologic safety in pregnancy. Lastly, a new predictive tool for psoriatic arthritis risk, PRESTO, identifies important clinical indicators like morning stiffness and psoriatic nail lesions that dermatologists should monitor in psoriasis patients.
View moreConclusions
- Bimekizumab is a new IL-17 inhibitor that works quickly and has shown superior efficacy compared to existing treatments.
- Bimekizumab is effective for patients with recalcitrant psoriasis who have failed other biologics, including other IL-17 inhibitors.
- Deucravacitinib is a selective oral tyrosine kinase inhibitor that demonstrates superior efficacy compared to apremilast and traditional JAK inhibitors.
- Deucravacitinib has a favorable safety profile, including a reassuring risk of malignancy and a lower rate of laboratory abnormalities than traditional JAK inhibitors.
- Tapinarof is the first non-steroidal topical agent for psoriasis in over 25 years, showing promising outcomes for inverse psoriasis but with a high incidence of folliculitis.
- Roflumilast is a newly approved non-steroidal treatment option for children that does not cause folliculitis.
- New biosimilars like ustekinumab-aaub increase treatment options for patients with psoriasis.
- Exposure to biologics in pregnancy shows no increased risk of miscarriage or congenital malformations, indicating relative safety for pregnant patients.
- A new risk estimation tool has been developed for assessing psoriatic arthritis in patients with psoriasis, focusing on specific clinical factors.
- Glatt S, et al. Ann Rheum Dis. 2018;77(4):523-532
- Lønnberg AS, et al. Clin Cosmet Investig Dermatol. 2014;7:251-259
- Warren RB, et al. N Engl J Med. 2021;385(2):130-141
- Reich K, et al. Lancet. 2021;397(10273):487-498
- Gordon KB, et al. Lancet. 2021;397(10273):475-486
- Chimalakonda A, et al. Dermatol. 2021;11(5):1763-1776
- Armstrong AW, et al. J Am Acad Dermatol. 2023;88(1):29-39
- Armstrong AW, et al. J Am Acad Dermatol. 2023;13(11):2839-2857
- Sánchez-García V, Hernández-Quiles R, et al. J Eur Dermatol. 2023;37(10):1971-1990
- Eder L, Lee K, et al. Arthritis Rhuematol. 2022;74(suppl 9)
- Strober B, Bissonnette R, et al. J Am Dermatol. 2022;87(4):800-806